LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio,” “Company,” “We,” “Us,” or “IMMX”), a leading clinical company—a pioneering biopharmaceutical corporation in mobile treatments for AL amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as the lead clinical center for its multiclinical trial in NXC-201 relapsed/refractory AL amyloidosis.
“We are anticipating this vital, multi-site clinical trial with NXC-201 CAR-T for patients with AL amyloidosis,” said Heather Landau, MD, director of the amyloidosis program at Memorial Sloan Kettering Cancer Center. “NXC-201 represents a new direction in the landscape of remedies for patients with relapsed or refractory AL amyloidosis. “
About NEXICART-2
NEXICART-2 (NCT06097832) is a Phase 1b, open-label, single-arm, multi-site, dose-extending clinical trial for the treatment of relapsed/refractory AL amyloidosis for CAR-T NXC-201 in the United States. NEXICART-2 is expected to enroll 40 patients over a period of approximately 18 months from first administration to the patient. The goals are the protection and power of the NXC-201. The number one expected endpoints are the total reaction rate and the overall reaction rate according to consensus recommendations (Palladini et al. 2012).
We believe that NXC-201 (formerly HBI0101) is the only single-day CRS CAR-T mobile cure targeting BCMA that is suitable for treating AL amyloidosis and other autoimmune diseases. It is being studied as a component of a comprehensive clinical progression program for the treatment of patients with relapsed/refractory AL amyloidosis and extended to other autoimmune indications. These trials are based on established physically powerful clinical knowledge about NXC-201 presented in February 2021. NXC-201 earned Orphan Drug Designation (ODD) through the FDA in the treatment of AL amyloidosis and multiple myeloma, and obtained EMA Orphan Drug Designation in the treatment of AL amyloidosis.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering mobile cures for AL amyloidosis and other autoimmune diseases. Our primary mobile cure is the FDA and IND approved next-generation CAR-T NXC-201. , which is recently being evaluated in our Phase 1b/2 clinical trial NEXICART-1 (NCT04720313), which began in February 2021. NXC-201 has the potential to be the world’s first single-day “SRC” CAR-T. (mean onset of CRS 1 day, mean duration 1 day), allowing for faster discharge for patients and supporting the continued expansion of autoimmune indications. NXC-201 has earned orphan drug designation (ODD) from the FDA in the treatment of AL amyloidosis and multiple myeloma and ODD from the European Commission (EMA) for the treatment of AL amyloidosis. Learn more about www. immixbio. com and www. BeProactiveInAL. com.
Forward-Looking Statements
ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors. com
Contact empresairteam@immixbio. com